MedTrace Logo

Vactosertib and Imatinib Combination in Patients with Advanced Desmoid Tumor/aggressive Fibromatosis (DT/AF)

NCT06219733 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2024-12-09

No results posted yet for this study

Summary

Vactosertib and imatinib combination in patients with advanced desmoid tumor/aggressive fibromatosis (DT/AF) compared with imatinib monotherapy

Conditions

  • Dermoid

Interventions

DRUG

Vactosertib

200 mg PO BID 5 days on / 2 days off

DRUG

Imatinib

Imatinib 400 mg PO QD daily

Sponsors & Collaborators

  • MedPacto, Inc.

    lead INDUSTRY

Principal Investigators

  • Sunjin Hwang, MD · MedPacto, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2022-05-23
Completion
2022-05-23

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06219733 on ClinicalTrials.gov